Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization.
Pharmaceutical compounds are molecular solids that frequently exhibit polymorphism of crystal form. One high profile case of polymorphism was ritonavir, a peptidomimetic drug used to treat HIV-1 infection and introduced in 1996. In 1998, a lower energy, more stable polymorph (form II) appeared, causing slowed dissolution of the marketed dosage form and compromising the oral bioavailability of the drug. This event forced the removal of the oral capsule formulation from the market. We have carried out high-throughput crystallization experiments to comprehensively explore ritonavir form diversity. A total of five forms were found: both known forms and three previously unknown forms. The novel forms include a metastable polymorph, a hydrate phase, and a formamide solvate. The solvate was converted to form I via the hydrate phase by using a simple washing procedure, providing an unusual route to prepare the form I "disappearing polymorph" [Dunitz, J. D. & Bernstein, J. (1995) Acc. Chem. Res. 28, 193-200]. Crystals of form I prepared by using this method retained the small needle morphology of the solvate and thus offer a potential strategy for particle size and morphology control.
Morissette
Sherry L
SL
TransForm Pharmaceuticals, Inc., 29 Hartwell Avenue, Lexington, MA 02421, USA. morissette@transformpharma.com
Soukasene
Stephen
S
Levinson
Douglas
D
Cima
Michael J
MJ
Almarsson
Orn
O
D018360:Crystallography, X-Ray; D017320:HIV Protease Inhibitors / Q000737:chemistry*; D010455:Peptides / Q000737:chemistry*; D019438:Ritonavir / Q000737:chemistry*; D013059:Spectrum Analysis, Raman; D013696:Temperature
D017320:HIV Protease Inhibitors; D010455:Peptides; D019438:Ritonavir